Cambridge-based Epizyme Raises $32 Million in Second Round

From New England Tech Wire



Cambridge, Mass. - Epizyme, a
Cambridge-based biopharmaceutical company, has raised $32 million in its second
round of venture capital, which was led by Bay City Capital, the company
announced. Founded in 2007, Epizyme is developing drugs for major diseases
based on new discoveries emerging from the field of epigenetics, which are
enzymes that play a critical role in serious diseases such as cancer. Other
investors in the deal include MPM Capital and Kleiner Perkins Caufield and
Byers.

http://www.epizyme.com/pr-10.7.09.html

Check out the jobs at Epizyme